AFMD News and Press, Affimed N.V. From 05/23/23

2023-05-23 07:16:13 ET German biotech Affimed N.V. ( NASDAQ: AFMD ) announced Tuesday that the FDA cleared an Investigational New Drug Application (IND) permitting a Phase 2 trial to study its innate cell engager AFM13 as a combination therapy for certain patients with Hodgkin Lymph...

2023-05-23 06:33:15 ET Affimed press release ( NASDAQ: AFMD ): Q1 GAAP EPS of -€0.21. Revenue of €4.51M (-43.7% Y/Y). As of March 31, 2023 cash and cash equivalents totaled €155.8 million compared to €190.3 million on December 31, 2022....

AFM13 combination with AB-101 NK cells: Received IND clearance from the FDA for a phase 2 clinical trial investigating the combination therapy in relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL) and peripheral T Cell Lymphoma (PTCL). Affimed expects to initiate clinical trial in Q3 2023...

Phase 2 combination study of AFM13 with AB-101 in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) will be an open-label, multi-center, multi-cohort study with a safety run-in followed by dose optimization and expansion phase Primary endpoints of the study are to assess the ant...

2023-05-22 12:53:45 ET Affimed ( NASDAQ: AFMD ) is scheduled to announce Q1 earnings results on Tuesday, May 23rd, before market open. The consensus EPS Estimate is -$0.21 and the consensus Revenue Estimate is $6.18M. Over the last 3 months, EPS estimates have seen 0 ...

2023-05-22 11:07:30 ET Major earnings expected before the bell on Tuesday include: DICK'S Sporting Goods ( DKS ) Eagle Point Credit ( ECC ) Jumia Technologies ( JMIA ) Lowe's Companies ( LOW ) Navios Maritime Partners ( NMM ) For further detai...

HEIDELBERG, Germany, May 16, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release first quarter 2023 results and corporate update on Tuesday, May ...

A post-hoc subgroup analysis from the AFM13 REDIRECT study in patients with relapsed/refractory (r/r) peripheral T cell lymphoma (PTCL) is accepted as a poster presentation A trial in progress abstract of the phase 1 dose escalation study to assess safety and tolerability of AFM28 monotherapy...

AFM24-101 phase 1/2 interim results from the non-small cell lung cancer cohort accepted for poster presentation AFM24-101 phase1/2 interim results from the colorectal cancer cohort accepted for online publication HEIDELBERG, Germany, April 26, 2023 (GLOBE NEWSWIRE) -- Affimed N.V....

The poster presentation highlights the relevance of CD16A shedding for serial killing by AFM13-engaged natural killer (NK) cells It demonstrates the potential of AFM13 to induce serial killing, even in tumor cells with low target expression HEIDELBERG, Germany, April 17, 2023 (GLOBE NEW...